Pfizer Pre-Tax Profit Margin 1986-2025 | PFE
Current and historical pre-tax profit margin for Pfizer (PFE) from 1986 to 2025. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. Pfizer pre-tax profit margin for the three months ending June 30, 2025 was .
| Pfizer Pre-Tax Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Pre-Tax Income |
Pre-Tax Margin |
| 2025-06-30 |
$63.83B |
$10.53B |
16.50% |
| 2025-03-31 |
$62.46B |
$7.39B |
11.83% |
| 2024-12-31 |
$63.63B |
$8.02B |
12.61% |
| 2024-09-30 |
$60.43B |
$3.90B |
6.46% |
| 2024-06-30 |
$56.22B |
$-4.16B |
-7.40% |
| 2024-03-31 |
$55.95B |
$-1.79B |
-3.20% |
| 2023-12-31 |
$59.55B |
$1.06B |
1.78% |
| 2023-09-30 |
$70.12B |
$10.42B |
14.86% |
| 2023-06-30 |
$79.27B |
$22.77B |
28.73% |
| 2023-03-31 |
$94.00B |
$31.95B |
33.99% |
| 2022-12-31 |
$101.18B |
$34.73B |
34.33% |
| 2022-09-30 |
$99.88B |
$33.33B |
33.37% |
| 2022-06-30 |
$101.28B |
$32.17B |
31.76% |
| 2022-03-31 |
$92.43B |
$27.67B |
29.93% |
| 2021-12-31 |
$81.29B |
$24.31B |
29.91% |
| 2021-09-30 |
$68.88B |
$21.08B |
30.61% |
| 2021-06-30 |
$55.12B |
$13.81B |
25.05% |
| 2021-03-31 |
$46.08B |
$9.89B |
21.45% |
| 2020-12-31 |
$41.65B |
$7.04B |
16.89% |
| 2020-09-30 |
$32.07B |
$-1.43B |
-4.47% |
| 2020-06-30 |
$34.47B |
$8.73B |
25.31% |
| 2020-03-31 |
$37.87B |
$9.84B |
25.98% |
| 2019-12-31 |
$40.91B |
$11.32B |
27.68% |
| 2019-09-30 |
$40.22B |
$9.95B |
24.75% |
| 2019-06-30 |
$40.84B |
$3.40B |
8.34% |
| 2019-03-31 |
$41.04B |
$3.79B |
9.24% |
| 2018-12-31 |
$40.83B |
$3.59B |
8.80% |
| 2018-09-30 |
$53.37B |
$13.79B |
25.83% |
| 2018-06-30 |
$53.24B |
$13.19B |
24.78% |
| 2018-03-31 |
$52.67B |
$12.48B |
23.70% |
| 2017-12-31 |
$52.55B |
$12.31B |
23.42% |
| 2017-09-30 |
$52.47B |
$12.13B |
23.11% |
| 2017-06-30 |
$52.35B |
$10.15B |
19.38% |
| 2017-03-31 |
$52.60B |
$8.74B |
16.62% |
| 2016-12-31 |
$52.82B |
$8.35B |
15.81% |
| 2016-09-30 |
$53.24B |
$7.22B |
13.56% |
| 2016-06-30 |
$52.29B |
$8.32B |
15.90% |
| 2016-03-31 |
$50.99B |
$9.44B |
18.52% |
| 2015-12-31 |
$48.85B |
$8.97B |
18.35% |
| 2015-09-30 |
$47.92B |
$11.12B |
23.21% |
| 2015-06-30 |
$48.20B |
$12.01B |
24.92% |
| 2015-03-31 |
$49.12B |
$12.48B |
25.40% |
| 2014-12-31 |
$49.61B |
$12.24B |
24.67% |
| 2014-09-30 |
$50.05B |
$13.50B |
26.97% |
| 2014-06-30 |
$50.33B |
$13.48B |
26.79% |
| 2014-03-31 |
$50.53B |
$14.84B |
29.37% |
| 2013-12-31 |
$51.58B |
$15.72B |
30.47% |
| 2013-09-30 |
$50.88B |
$14.48B |
28.45% |
| 2013-06-30 |
$51.19B |
$13.71B |
26.78% |
| 2013-03-31 |
$52.18B |
$12.53B |
24.02% |
| 2012-12-31 |
$54.66B |
$11.24B |
20.57% |
| 2012-09-30 |
$53.25B |
$10.65B |
19.99% |
| 2012-06-30 |
$56.90B |
$11.38B |
20.00% |
| 2012-03-31 |
$59.42B |
$10.80B |
18.17% |
| 2011-12-31 |
$61.04B |
$11.48B |
18.81% |
| 2011-09-30 |
$65.06B |
$11.24B |
17.28% |
| 2011-06-30 |
$64.44B |
$9.11B |
14.14% |
| 2011-03-31 |
$65.09B |
$9.44B |
14.50% |
| 2010-12-31 |
$65.17B |
$9.47B |
14.53% |
| 2010-09-30 |
$65.50B |
$8.34B |
12.73% |
| 2010-06-30 |
$61.13B |
$10.90B |
17.83% |
| 2010-03-31 |
$54.98B |
$10.02B |
18.23% |
| 2009-12-31 |
$49.27B |
$10.67B |
21.66% |
| 2009-09-30 |
$45.82B |
$11.45B |
24.99% |
| 2009-06-30 |
$46.17B |
$10.20B |
22.09% |
| 2009-03-31 |
$47.32B |
$9.94B |
21.01% |
| 2008-12-31 |
$48.30B |
$9.69B |
20.07% |
| 2008-09-30 |
$48.82B |
$12.04B |
24.66% |
| 2008-06-30 |
$48.84B |
$9.95B |
20.38% |
| 2008-03-31 |
$47.79B |
$8.78B |
18.38% |
| 2007-12-31 |
$48.42B |
$9.28B |
19.16% |
| 2007-09-30 |
$48.15B |
$8.02B |
16.66% |
| 2007-06-30 |
$48.44B |
$11.35B |
23.42% |
| 2007-03-31 |
$49.10B |
$12.81B |
26.09% |
| 2006-12-31 |
$48.37B |
$13.03B |
26.93% |
| 2006-09-30 |
$47.37B |
$14.28B |
30.15% |
| 2006-06-30 |
$46.35B |
$12.33B |
26.60% |
| 2006-03-31 |
$46.06B |
$12.16B |
26.40% |
| 2005-12-31 |
$47.41B |
$10.80B |
22.78% |
| 2005-09-30 |
$47.20B |
$10.73B |
22.73% |
| 2005-06-30 |
$48.77B |
$12.67B |
25.97% |
| 2005-03-31 |
$49.59B |
$13.18B |
26.58% |
| 2004-12-31 |
$48.99B |
$13.40B |
27.36% |
| 2004-09-30 |
$51.57B |
$11.46B |
22.21% |
| 2004-06-30 |
$51.09B |
$9.99B |
19.56% |
| 2004-03-31 |
$48.72B |
$3.16B |
6.48% |
| 2003-12-31 |
$44.74B |
$3.25B |
7.26% |
| 2003-09-30 |
$40.01B |
$5.73B |
14.33% |
| 2003-06-30 |
$35.66B |
$6.14B |
17.23% |
| 2003-03-31 |
$33.05B |
$11.92B |
36.07% |
| 2002-12-31 |
$32.29B |
$11.77B |
36.43% |
| 2002-09-30 |
$29.03B |
$10.57B |
36.41% |
| 2002-06-30 |
$28.86B |
$10.43B |
36.12% |
| 2002-03-31 |
$29.19B |
$10.44B |
35.78% |
| 2001-12-31 |
$29.02B |
$9.98B |
34.40% |
| 2001-09-30 |
$31.14B |
$8.46B |
27.18% |
| 2001-06-30 |
$30.47B |
$7.49B |
24.59% |
| 2001-03-31 |
$29.84B |
$6.77B |
22.68% |
| 2000-12-31 |
$29.41B |
$4.58B |
15.56% |
| 2000-09-30 |
$25.81B |
$5.17B |
20.01% |
| 2000-06-30 |
$21.99B |
$4.35B |
19.78% |
| 2000-03-31 |
$18.78B |
$3.71B |
19.75% |
| 1999-12-31 |
$15.54B |
$4.45B |
28.62% |
| 1999-09-30 |
$14.90B |
$3.17B |
21.30% |
| 1999-06-30 |
$14.90B |
$2.91B |
19.52% |
| 1999-03-31 |
$14.24B |
$2.78B |
19.53% |
| 1998-12-31 |
$13.35B |
$2.59B |
19.44% |
| 1998-09-30 |
$12.39B |
$3.34B |
26.98% |
| 1998-06-30 |
$11.71B |
$3.45B |
29.48% |
| 1998-03-31 |
$11.09B |
$3.19B |
28.75% |
| 1997-12-31 |
$10.74B |
$3.09B |
28.76% |
| 1997-09-30 |
$10.99B |
$3.04B |
27.65% |
| 1997-06-30 |
$11.14B |
$2.98B |
26.71% |
| 1997-03-31 |
$11.31B |
$2.91B |
25.76% |
| 1996-12-31 |
$11.31B |
$2.80B |
24.80% |
| 1996-09-30 |
$10.89B |
$2.64B |
24.25% |
| 1996-06-30 |
$10.63B |
$2.52B |
23.71% |
| 1996-03-31 |
$10.37B |
$2.42B |
23.36% |
| 1995-12-31 |
$10.02B |
$2.30B |
22.95% |
| 1995-09-30 |
$9.58B |
$2.21B |
23.11% |
| 1995-06-30 |
$9.11B |
$2.07B |
22.70% |
| 1995-03-31 |
$8.64B |
$1.96B |
22.73% |
| 1994-12-31 |
$8.28B |
$1.86B |
22.49% |
| 1994-09-30 |
$7.97B |
$1.78B |
22.27% |
| 1994-06-30 |
$7.77B |
$0.96B |
12.41% |
| 1994-03-31 |
$7.59B |
$0.94B |
12.35% |
| 1993-12-31 |
$7.48B |
$0.85B |
11.39% |
| 1993-09-30 |
$7.44B |
$0.87B |
11.63% |
| 1993-06-30 |
$7.39B |
$1.60B |
21.58% |
| 1993-03-31 |
$7.34B |
$1.58B |
21.52% |
| 1992-12-31 |
$7.23B |
$1.53B |
21.22% |
| 1992-09-30 |
$7.13B |
$1.10B |
15.35% |
| 1992-06-30 |
$7.08B |
$1.06B |
14.93% |
| 1992-03-31 |
$7.02B |
$0.98B |
13.90% |
| 1991-12-31 |
$6.95B |
$0.94B |
13.58% |
| 1991-09-30 |
$6.89B |
$1.19B |
17.30% |
| 1991-06-30 |
$6.76B |
$1.16B |
17.20% |
| 1991-03-31 |
$6.62B |
$1.13B |
16.99% |
| 1990-12-31 |
$6.41B |
$1.10B |
17.23% |
| 1990-09-30 |
$6.12B |
$0.98B |
16.08% |
| 1990-06-30 |
$5.91B |
$0.95B |
16.04% |
| 1990-03-31 |
$5.72B |
$0.93B |
16.25% |
| 1989-12-31 |
$5.67B |
$0.92B |
16.17% |
| 1989-09-30 |
$5.55B |
$1.02B |
18.46% |
| 1989-06-30 |
$5.49B |
$1.03B |
18.78% |
| 1989-03-31 |
$5.52B |
$1.13B |
20.51% |
| 1988-12-31 |
$5.39B |
$1.10B |
20.50% |
| 1988-09-30 |
$5.29B |
$1.09B |
20.54% |
| 1988-06-30 |
$5.21B |
$1.06B |
20.34% |
| 1988-03-31 |
$5.10B |
$1.03B |
20.16% |
| 1987-12-31 |
$4.92B |
$1.01B |
20.57% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$201.199B |
$100.330B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
